- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00622427
Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia
April 2, 2013 updated by: Rachel Fargason, MD, University of Alabama at Birmingham
Primary: We hypothesize a clinically significant improvement in sleep latency, sleep-onset and total sleep time measures in adults with ADHD when given a trial of Ramelteon compared to placebo.
Secondary:We expect that Ramelteon will show statistically significant improvements vs. placebo in measures of daytime sleepiness and with no decrement in daytime functioning, including such specific items as focus and social and occupational functioning.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Method: 8-week, randomized, double-blind, placebo-controlled crossover trial of Ramelteon in adult ADHD subjects who suffer from initial insomnia.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of ADHD and insomnia-
- 19-65 years of age
- In good general health
- Negative pregnancy test
Exclusion Criteria:
- Current primary psychiatric diagnosis other than ADHD
- Positive urine drug screen for any sedative hypnotic or drugs of abuse
- Unstable medical condition
- HIV positive
- Seizure disorder
- Known hypersensitivity to Ramelteon
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ramelteon then placebo
8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
|
8 mg tablets every night for 2 weeks
Other Names:
|
Experimental: Placebo then Ramelteon
placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
|
placebo tablets for every night for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Baseline to 2 Weeks ADHD Rating Scale
Time Frame: day 1 to day 14 of study drug
|
It is an 18 item scale with 9 symptoms of inattention and 9 symptoms of Impulsivity and Hyperactivity.
This scale is the gold standard in assessment of ADHD.
Scores range from 0-54.
There must be a score of 6 or more in either category to be diagnosed with ADHD.
Severity ranges: 6-18 mild, 19-36 moderate, 37-54 severe.
The outcome measure is the percentage difference between the total day 1 score for all subjects and the total 14 day score for all subjects.
|
day 1 to day 14 of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinical Global Impression (CGI)
Time Frame: day 1 to day 14 of study drug
|
The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients).
The outcome measure is the percent difference between the total score for all subjects at day 1 and the total score for all subjects at day 14 of the study drug.
|
day 1 to day 14 of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
February 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
February 13, 2008
First Submitted That Met QC Criteria
February 22, 2008
First Posted (Estimate)
February 25, 2008
Study Record Updates
Last Update Posted (Estimate)
May 24, 2013
Last Update Submitted That Met QC Criteria
April 2, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F071204001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD With Sleep Onset Insomnia
-
University Hospital, Strasbourg, FranceRecruitingAdult ADHD | Adult-onset ADHD With Mood DisorderFrance
-
Brigham and Women's HospitalCompleted
-
Rhode Island HospitalEli Lilly and CompanyUnknownInsomnia | Attention-Deficit/Hyperactivity Disorder (ADHD)United States
-
The University of Hong KongChinese University of Hong KongRecruiting
-
The University of Hong KongKwai Chung Hospital, Hong KongRecruiting
-
Taisho Pharmaceutical Co., Ltd.Completed
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownPrimary Insomnia | Depressive Disorders With InsomniaTaiwan
-
Taisho Pharmaceutical Co., Ltd.Completed
-
Taisho Pharmaceutical Co., Ltd.Completed
-
National Jewish HealthCompletedHypnotic Dependence Among Those With InsomniaUnited States
Clinical Trials on Ramelteon
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
TakedaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States
-
TakedaCompletedSleep Apnea, ObstructiveUnited States
-
Southern Arizona VA Health Care SystemUnknownGastroesophageal Reflux Disease | Chronic InsomniaUnited States
-
Centennial Medical CenterRecruiting
-
University of California, San DiegoActive, not recruitingDelirium | Sleep Deprivation
-
TakedaCompleted
-
Massachusetts General HospitalWithdrawnParkinson's Disease | Sleep Disorders | Dementia With Lewy Bodies | Huntington's Disease | Circadian DysregulationUnited States
-
Charlottesville NeuroscienceTakeda Pharmaceuticals North America, Inc.TerminatedMigraine HeadacheUnited States
-
TakedaCompletedChronic InsomniaUnited States